The Manipal Health IPO opens for subscription on Wednesday, drawing a cautious response from investors despite strong backing from brokerages. While retail investors showed early interest, the grey market premium (GMP) remained subdued, indicating modest listing expectations.
The ₹9,275-crore public issue is one of the biggest healthcare IPOs of the year and comes at a time when investors are becoming increasingly selective about valuations. The key question now is whether the muted GMP reflects limited listing gains or an attractive long-term investment opportunity.
Track Live : IPO – Latest & Upcoming IPOs List 2026 | Check Live BSE NSE IPOs
IPO Timeline
| Event | Date |
|---|---|
| IPO Opens | July 29, 2026 |
| IPO Closes | July 31, 2026 |
| Allotment | August 3, 2026 |
| Refunds | August 4, 2026 |
| Shares Credited | August 4, 2026 |
| Listing | August 5, 2026 |
Manipal Health IPO opens subscription begins with steady retail participation
The Manipal Health IPO opened for bidding on July 29 and will remain open until July 31.
As of 12:49 pm on Day 1, the IPO was subscribed 0.05 times, according to NSE data.
The category-wise subscription stood at:
- Retail Investors (RII): 0.18x
- Non-Institutional Investors (NII): 0.05x
- Qualified Institutional Buyers (QIB – Ex Anchor): 0.00x
- Employees: 0.69x
Earlier in the morning, the issue had crossed the 2% overall subscription mark, with retail investors leading the initial demand.
The IPO has a price band of ₹560-590 per share, and investors can bid in a minimum lot size of 25 shares, requiring an investment of ₹14,750 at the upper price band.
| Particulars | Details |
|---|---|
| IPO Type | Bookbuilding IPO |
| Issue Size | ₹9,275 Cr |
| IPO Dates | July 29 – July 31, 2026 |
| Listing Date (Tentative) | August 5, 2026 |
| Price Band | ₹560 – ₹590 |
| Face Value | ₹2 |
| Lot Size | 25 Shares |
| Listing | BSE & NSE |
Manipal Health IPO GMP remains muted on Day 1
Grey market sentiment has remained soft despite the company’s strong market position.
As of July 29 (12:35 pm), the Manipal Health IPO GMP stood at ₹9 per share, implying an estimated listing price of ₹599, or a potential listing gain of around 1.53% over the upper price band.
Read More : MCX Crude Oil Climbs Over 4% as Middle East Conflict Raises Supply Disruption Risks
The GMP has been trending lower over the past week.
| Date | GMP | Estimated Listing Gain |
|---|---|---|
| July 24 | ₹35 | 5.93% |
| July 25 | ₹25 | 4.24% |
| July 26 | ₹25 | 4.24% |
| July 27 | ₹13 | 2.20% |
| July 28 | ₹10 | 1.69% |
| July 29 | ₹9 | 1.53% |
Investors should note that grey market premiums are unofficial indicators and should not be considered a guarantee of listing performance.
GMP Update
| Metric | Value |
|---|---|
| Latest GMP | ₹9 |
| Upper Price Band | ₹590 |
| Estimated Listing Price | ₹599 |
| Expected Listing Gain | 1.53% |
Issue structure and how the company plans to use the funds
The ₹9,275-crore book-built issue comprises:
- Fresh Issue: ₹8,000 crore
- Offer for Sale (OFS): ₹1,275 crore
The OFS has been reduced from the original proposal in the draft prospectus, lowering the selling component by existing shareholders, including TPG and Novo Holdings.
The company plans to utilize the fresh proceeds primarily for:
- Repayment of borrowings of Manipal Hospitals Private Limited
- Acquisition of a minority stake in Sahyadri Hospitals Private Limited
- General corporate purposes
The basis of allotment is expected on August 3, while the shares are tentatively scheduled to list on the BSE and NSE on August 5.
Day 1 Subscription Status (As of 12:49 PM IST)
| Category | Subscription |
|---|---|
| QIB (Ex-Anchor) | 0.00x |
| NII | 0.05x |
| Retail | 0.18x |
| Employees | 0.69x |
| Overall | 0.05x |
Strong financial performance supports the investment case
Manipal Health Enterprises has reported healthy business growth over the past year.
For FY26, the company posted:
Financial Highlights (FY26)
| Metric | Value |
|---|---|
| Revenue | ₹10,335.75 Cr |
| Net Profit | ₹892.32 Cr |
| ROCE | 21.88% |
| RoNW | 10.57% |
| EBITDA Margin | 27.05% |
| PAT Margin | 8.87% |
| Price-to-Book | 8.13x |
| P/E (Upper Band) | 85.4x |
As of March 2026, the hospital chain operated 49 hospitals with 13,037 licensed beds across 14 states and union territories, making it one of India’s largest multi-specialty healthcare providers.
Key Positives vs Risks
| Positives | Risks |
|---|---|
| Leading hospital network with 49 hospitals | IPO fully priced at upper band |
| Strong FY26 revenue and profit growth | GMP indicates limited listing gains |
| Expansion through debt reduction and acquisitions | Weak Day 1 institutional participation |
| Long-term healthcare demand tailwind | Premium valuation (85.4x P/E) |
Brokerages recommend a long-term view
Despite the muted GMP, most brokerage houses remain positive on the company’s long-term prospects.
Master Capital Services said:
“Manipal Health Enterprises Limited is well positioned to benefit from growing healthcare demand, supported by its pan-India network, strong presence across key metro and non-metro markets, focus on tertiary and quaternary care, advanced clinical capabilities and continued capacity expansion.”
Meanwhile, Anand Rathi noted that the IPO appears fully priced at the upper end of the valuation band.
At the issue price, the company is valued at a P/E multiple of 85.4 times FY26 earnings, with a post-issue market capitalization of around ₹77,605.6 crore.
The brokerage added:
“We believe that the IPO is fully priced and recommend a ‘Subscribe-Long Term’ rating to the IPO.”
Here’s what happened today and why traders reacted
The Manipal Health IPO received a measured response on its opening day as investors balanced the company’s strong fundamentals against relatively expensive valuations and a declining GMP.
Retail participation remained healthy, while institutional investors are expected to become more active over the remaining subscription period. The falling grey market premium also prompted investors looking for quick listing gains to remain cautious.
Should investors apply for the Manipal Health IPO?
The Manipal Health IPO may not appeal to investors seeking substantial listing gains, as the current GMP suggests only a modest premium at listing.
However, long-term investors may find the issue attractive because of the company’s leadership in India’s hospital sector, expanding healthcare network, improving financial performance, and plans to reduce debt through the IPO proceeds.
For traders, listing gains could remain limited unless subscription demand picks up significantly during the remaining bidding period. Long-term investors, however, may consider the IPO based on the company’s growth potential, healthcare sector tailwinds, and strong operational footprint rather than relying solely on short-term GMP trends.
